schliessen

Filtern

 

Bibliotheken

Effects of acipimox and cholestyramine on serum lipoproteins, non-cholesterol sterols and cholesterol absorption and elimination

The hypolipidaemic and metabolic effects of cholestyramine combined with acipimox or placebo have been evaluated in a double-blind ninety-day study in 18 patients with xanthomatous familial hypercholesterolaemia. Serum LDL-cholesterol was reduced by 35% in the cholestyramine group and 39% in the aci... Full description

Journal Title: European journal of clinical pharmacology 1989, Vol.37 (2), p.111-115
Main Author: GYLLING, H
Other Authors: VANHANEN, H , MIETTINEN, T. A
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: Heidelberg: Springer
ID: ISSN: 0031-6970
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_79225113
title: Effects of acipimox and cholestyramine on serum lipoproteins, non-cholesterol sterols and cholesterol absorption and elimination
format: Article
creator:
  • GYLLING, H
  • VANHANEN, H
  • MIETTINEN, T. A
subjects:
  • Adult
  • Apolipoproteins E - blood
  • Biological and medical sciences
  • Cholesterol - blood
  • Cholesterol - pharmacokinetics
  • Cholesterol, LDL - blood
  • Cholestyramine Resin - pharmacology
  • Double-Blind Method
  • Feces - analysis
  • Female
  • General and cellular metabolism. Vitamins
  • Humans
  • Hypolipidemic Agents - pharmacology
  • Intestinal Absorption
  • Lipids - blood
  • Lipoproteins - blood
  • Male
  • Medical sciences
  • Pharmacology. Drug treatments
  • Phenotype
  • Pyrazines - pharmacology
  • Squalene - blood
  • Sterols - blood
  • Sterols - pharmacokinetics
ispartof: European journal of clinical pharmacology, 1989, Vol.37 (2), p.111-115
description: The hypolipidaemic and metabolic effects of cholestyramine combined with acipimox or placebo have been evaluated in a double-blind ninety-day study in 18 patients with xanthomatous familial hypercholesterolaemia. Serum LDL-cholesterol was reduced by 35% in the cholestyramine group and 39% in the acipimoxcholestyramine group. The latter treatment increased the HDL-cholesterol level. Serum VLDL-cholesterol and triglyceride concentrations were unchanged. Cholesterol absorption efficiency was significantly reduced, and bile acid synthesis and faecal cholesterol elimination in both groups were increased. The metabolic changes were similar in the two treatment groups, but the increase in faecal neutral sterol excretion was significant only when acipimox was added. The serum cholesterol precursor sterol contents were similarly increased during the two treatments, indicating enhancement of endogenous cholesterol synthesis. The decrease in cholesterol absorption and the increase in neutral sterol excretion were more pronounced in subjects with greater than 30% than in those with less than 30% reduction in LDL-cholesterol. The changes in serum total and LDL-cholesterol levels and cholesterol metabolism were not related to apoE phenotype, but the increase in HDL-cholesterol was higher in E4 then in E3 subjects.
language: eng
source:
identifier: ISSN: 0031-6970
fulltext: no_fulltext
issn:
  • 0031-6970
  • 1432-1041
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK1.5162233
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_cross
recordidTN_cdi_proquest_miscellaneous_79225113
sourceformatXML
sourcesystemPC
sourcerecordid79225113
originalsourceidFETCH-LOGICAL-c262t-a269b1d98b526f0a85897f62a12253aa3759e8aa2a0e76e53c02d11eeddac6c30
addsrcrecordideNpNkEFLw0AQRhdRaq1evAt7EA9idHbT3SRHLa0KBS96DtPNBFeSbNxNwd786aY2VE_DzPd4DB9j5wJuBUBy97AAUCqVQh-wsZjGMhIwFYdsDBCLSGcJHLOTED4AhMogHrGRTLKeno7Z97wsyXSBu5Kjsa2t3RfHpuDm3VUUuo3H2jbEXcMD-XXNK9u61ruObBNueOOaaCDJu4rvRvhv-L3jKjjfdrbXbCOqbG_F7X7KjkqsAp0Nc8LeFvPX2VO0fHl8nt0vIyO17CKUOluJIktXSuoSMFVplpRaopBSxYhxojJKESUCJZpUbEAWQhAVBRptYpiwq523f_5z3f-V1zYYqipsyK1D3hcilRBb8HoHGu9C8FTmrbc1-k0uIN_Wnf_V3cMXg3W9qqnYo0O_fX455BgMVqXHxtiwx3SiIFNT-AEiRYnA
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid79225113
display
typearticle
titleEffects of acipimox and cholestyramine on serum lipoproteins, non-cholesterol sterols and cholesterol absorption and elimination
creatorGYLLING, H ; VANHANEN, H ; MIETTINEN, T. A
creatorcontribGYLLING, H ; VANHANEN, H ; MIETTINEN, T. A
descriptionThe hypolipidaemic and metabolic effects of cholestyramine combined with acipimox or placebo have been evaluated in a double-blind ninety-day study in 18 patients with xanthomatous familial hypercholesterolaemia. Serum LDL-cholesterol was reduced by 35% in the cholestyramine group and 39% in the acipimoxcholestyramine group. The latter treatment increased the HDL-cholesterol level. Serum VLDL-cholesterol and triglyceride concentrations were unchanged. Cholesterol absorption efficiency was significantly reduced, and bile acid synthesis and faecal cholesterol elimination in both groups were increased. The metabolic changes were similar in the two treatment groups, but the increase in faecal neutral sterol excretion was significant only when acipimox was added. The serum cholesterol precursor sterol contents were similarly increased during the two treatments, indicating enhancement of endogenous cholesterol synthesis. The decrease in cholesterol absorption and the increase in neutral sterol excretion were more pronounced in subjects with greater than 30% than in those with less than 30% reduction in LDL-cholesterol. The changes in serum total and LDL-cholesterol levels and cholesterol metabolism were not related to apoE phenotype, but the increase in HDL-cholesterol was higher in E4 then in E3 subjects.
identifier
0ISSN: 0031-6970
1EISSN: 1432-1041
2DOI: 10.1007/BF00558216
3PMID: 2792164
languageeng
publisherHeidelberg: Springer
subjectAdult ; Apolipoproteins E - blood ; Biological and medical sciences ; Cholesterol - blood ; Cholesterol - pharmacokinetics ; Cholesterol, LDL - blood ; Cholestyramine Resin - pharmacology ; Double-Blind Method ; Feces - analysis ; Female ; General and cellular metabolism. Vitamins ; Humans ; Hypolipidemic Agents - pharmacology ; Intestinal Absorption ; Lipids - blood ; Lipoproteins - blood ; Male ; Medical sciences ; Pharmacology. Drug treatments ; Phenotype ; Pyrazines - pharmacology ; Squalene - blood ; Sterols - blood ; Sterols - pharmacokinetics
ispartofEuropean journal of clinical pharmacology, 1989, Vol.37 (2), p.111-115
rights1990 INIST-CNRS
lds50peer_reviewed
citesFETCH-LOGICAL-c262t-a269b1d98b526f0a85897f62a12253aa3759e8aa2a0e76e53c02d11eeddac6c30
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6750954$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2792164$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0GYLLING, H
1VANHANEN, H
2MIETTINEN, T. A
title
0Effects of acipimox and cholestyramine on serum lipoproteins, non-cholesterol sterols and cholesterol absorption and elimination
1European journal of clinical pharmacology
addtitleEur J Clin Pharmacol
descriptionThe hypolipidaemic and metabolic effects of cholestyramine combined with acipimox or placebo have been evaluated in a double-blind ninety-day study in 18 patients with xanthomatous familial hypercholesterolaemia. Serum LDL-cholesterol was reduced by 35% in the cholestyramine group and 39% in the acipimoxcholestyramine group. The latter treatment increased the HDL-cholesterol level. Serum VLDL-cholesterol and triglyceride concentrations were unchanged. Cholesterol absorption efficiency was significantly reduced, and bile acid synthesis and faecal cholesterol elimination in both groups were increased. The metabolic changes were similar in the two treatment groups, but the increase in faecal neutral sterol excretion was significant only when acipimox was added. The serum cholesterol precursor sterol contents were similarly increased during the two treatments, indicating enhancement of endogenous cholesterol synthesis. The decrease in cholesterol absorption and the increase in neutral sterol excretion were more pronounced in subjects with greater than 30% than in those with less than 30% reduction in LDL-cholesterol. The changes in serum total and LDL-cholesterol levels and cholesterol metabolism were not related to apoE phenotype, but the increase in HDL-cholesterol was higher in E4 then in E3 subjects.
subject
0Adult
1Apolipoproteins E - blood
2Biological and medical sciences
3Cholesterol - blood
4Cholesterol - pharmacokinetics
5Cholesterol, LDL - blood
6Cholestyramine Resin - pharmacology
7Double-Blind Method
8Feces - analysis
9Female
10General and cellular metabolism. Vitamins
11Humans
12Hypolipidemic Agents - pharmacology
13Intestinal Absorption
14Lipids - blood
15Lipoproteins - blood
16Male
17Medical sciences
18Pharmacology. Drug treatments
19Phenotype
20Pyrazines - pharmacology
21Squalene - blood
22Sterols - blood
23Sterols - pharmacokinetics
issn
00031-6970
11432-1041
fulltextfalse
rsrctypearticle
creationdate1989
recordtypearticle
recordideNpNkEFLw0AQRhdRaq1evAt7EA9idHbT3SRHLa0KBS96DtPNBFeSbNxNwd786aY2VE_DzPd4DB9j5wJuBUBy97AAUCqVQh-wsZjGMhIwFYdsDBCLSGcJHLOTED4AhMogHrGRTLKeno7Z97wsyXSBu5Kjsa2t3RfHpuDm3VUUuo3H2jbEXcMD-XXNK9u61ruObBNueOOaaCDJu4rvRvhv-L3jKjjfdrbXbCOqbG_F7X7KjkqsAp0Nc8LeFvPX2VO0fHl8nt0vIyO17CKUOluJIktXSuoSMFVplpRaopBSxYhxojJKESUCJZpUbEAWQhAVBRptYpiwq523f_5z3f-V1zYYqipsyK1D3hcilRBb8HoHGu9C8FTmrbc1-k0uIN_Wnf_V3cMXg3W9qqnYo0O_fX455BgMVqXHxtiwx3SiIFNT-AEiRYnA
startdate1989
enddate1989
creator
0GYLLING, H
1VANHANEN, H
2MIETTINEN, T. A
generalSpringer
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
97X8
sort
creationdate1989
titleEffects of acipimox and cholestyramine on serum lipoproteins, non-cholesterol sterols and cholesterol absorption and elimination
authorGYLLING, H ; VANHANEN, H ; MIETTINEN, T. A
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c262t-a269b1d98b526f0a85897f62a12253aa3759e8aa2a0e76e53c02d11eeddac6c30
rsrctypearticles
prefilterarticles
languageeng
creationdate1989
topic
0Adult
1Apolipoproteins E - blood
2Biological and medical sciences
3Cholesterol - blood
4Cholesterol - pharmacokinetics
5Cholesterol, LDL - blood
6Cholestyramine Resin - pharmacology
7Double-Blind Method
8Feces - analysis
9Female
10General and cellular metabolism. Vitamins
11Humans
12Hypolipidemic Agents - pharmacology
13Intestinal Absorption
14Lipids - blood
15Lipoproteins - blood
16Male
17Medical sciences
18Pharmacology. Drug treatments
19Phenotype
20Pyrazines - pharmacology
21Squalene - blood
22Sterols - blood
23Sterols - pharmacokinetics
toplevelpeer_reviewed
creatorcontrib
0GYLLING, H
1VANHANEN, H
2MIETTINEN, T. A
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8MEDLINE - Academic
jtitleEuropean journal of clinical pharmacology
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0GYLLING, H
1VANHANEN, H
2MIETTINEN, T. A
formatjournal
genrearticle
ristypeJOUR
atitleEffects of acipimox and cholestyramine on serum lipoproteins, non-cholesterol sterols and cholesterol absorption and elimination
jtitleEuropean journal of clinical pharmacology
addtitleEur J Clin Pharmacol
date1989
risdate1989
volume37
issue2
spage111
epage115
pages111-115
issn0031-6970
eissn1432-1041
abstractThe hypolipidaemic and metabolic effects of cholestyramine combined with acipimox or placebo have been evaluated in a double-blind ninety-day study in 18 patients with xanthomatous familial hypercholesterolaemia. Serum LDL-cholesterol was reduced by 35% in the cholestyramine group and 39% in the acipimoxcholestyramine group. The latter treatment increased the HDL-cholesterol level. Serum VLDL-cholesterol and triglyceride concentrations were unchanged. Cholesterol absorption efficiency was significantly reduced, and bile acid synthesis and faecal cholesterol elimination in both groups were increased. The metabolic changes were similar in the two treatment groups, but the increase in faecal neutral sterol excretion was significant only when acipimox was added. The serum cholesterol precursor sterol contents were similarly increased during the two treatments, indicating enhancement of endogenous cholesterol synthesis. The decrease in cholesterol absorption and the increase in neutral sterol excretion were more pronounced in subjects with greater than 30% than in those with less than 30% reduction in LDL-cholesterol. The changes in serum total and LDL-cholesterol levels and cholesterol metabolism were not related to apoE phenotype, but the increase in HDL-cholesterol was higher in E4 then in E3 subjects.
cop
0Heidelberg
1Berlin
pubSpringer
pmid2792164
doi10.1007/BF00558216